Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of TQB3473 in adults with chronic primary immune thrombocytopenia
ChiCTR2500100803Phase 3Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of TQB3473 in immune thrombocytopenia (ITP) (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Sustained response rate. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
TQB3473
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on ChiCTR2500100803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100803.